Correlation of Bispectral Index Score and Total Intravenous Anesthesia (TIVA)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Anesthesia, Rutgers, The State University of New Jersey Identifier:
First received: June 5, 2012
Last updated: June 9, 2015
Last verified: June 2015
General Anesthesia is usually produced by an intravenous agent and then maintained with a breathing agent till the surgery is completed. However, there is a recent trend to produce and maintain general anesthesia solely with an intravenous agent, such as propofol, in view of its advantages. This delivery method is called Total Intravenous Anesthesia (TIVA). The depth of general anesthesia can be measured by an anesthetic depth monitoring device called Bispectral Index (BIS). The use of BIS to determine the depth of anesthesia has been well established whenever a breathing agent is used to maintain general anesthesia. However, the validity of using BIS with TIVA has not been adequately investigated. This study will compare the BIS values at different doses of TIVA in order to establish any correlation between the two. If such a correlation is established, BIS monitoring can safely be recommended to determine anesthetic depth under TIVA.

Condition Intervention
Gynecology for Benign/Malignant Neoplasm.
Long Bone Fracture
Drug: propofol

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Study to Establish a Correlation Between Infusion Rate of Propofol and Bispectral Index (BIS) in Patients Receiving Total Intravenous Anesthesia (TIVA)

Resource links provided by NLM:

Further study details as provided by Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • BIS response to varying TIVA dosages [ Time Frame: 3 hours ] [ Designated as safety issue: No ]
    Correlation between various infusion rates of propofol administered during TIVA and BIS values during the first 3 hours of the operative procedure

Estimated Enrollment: 40
Study Start Date: June 2012
Estimated Study Completion Date: December 2015
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: propofol
    varying intravenous dosages
Detailed Description:

Pre-anesthetic Management: This research will be initiated after receiving an approval from the Institution Review Board, and an informed written consent will be obtained from each patient. Forty patients in the age range 18-65 years and presenting for elective orthopedic or gynecological procedures will be recruited. Both male and female patients will be considered. Only patients with American Society of Anesthesiologists (ASA) physical status I, II and III will be included. Patients who are pregnant and those with uncontrolled hypertension with BP above 180/100, unstable angina, chronic obstructive lung disease requiring oxygen therapy at home, and end-stage liver and kidney diseases will be excluded. In addition, orthopedic surgery that needs the patient in prone position will not be eligible for this investigation. Patients who have a medication allergy to propofol and food allergy to egg and soy, since egg lecithin and soy milk are constituents of propofol preparation, will be excluded. In order to have a complete data collection, only surgical procedures scheduled to last more than three hours will be considered for this study.

Anesthetic Management: Routine anesthetic care, such as intravenous line placement and American Society of Anesthesiologists' standard monitoring, will be applied to all patients. In addition, a non-invasive Bispectral Index (BIS) sensor will be placed on patient's forehead and connected to its monitor. Midazolam (25mcg/kg) and fentanyl (1mcg/kg) will be administered to establish preanesthetic sedation and analgesia, respectively. Lidocaine 40mg will be given to attenuate propofol-induced injection pain. Thereafter, Total Intravenous Anesthesia (TIVA) will be induced with propofol (2mg/kg), and tracheal intubation facilitated with a neuromuscular blocking agent chosen by the attending anesthesiologist. The skeletal muscle relaxation will be maintained as needed for the surgical procedure. The TIVA will be maintained with propofol infusion, for approximately half-hour, at 160mcg/kg/min with minor adjustment, as needed, to maintain patient's vital signs within ± 20% of the baseline. Once a steady state is established, propofol infusion rate will be reduced to 140mcg/kg/min and maintained for approximately 15-30 min, following which the infusion rate will be increased to 180mcg/kg/min and maintained for the same period of time. Thereafter, the propofol infusion rate will be returned to 160mcg/kg/min. This exercise will be repeated at 120mcg/kg/min and 200mcg/kg/min if patient's vital signs permit. In addition, remifentanil at an infusion rate of 0.02 - 0.2mcg/kg/min will be administered to provide surgical analgesia during the general anesthetic period. The infusion rate of remifentanil will be tailored to the demands of the surgical stimulation. During the study period, the attending anesthesiologist will have the option to deviate from the study protocol and adjust the propofol infusion rate, as needed, to maintain patient's vital signs within ± 20% of the baseline if such a need arises. An independent observer will continuously monitor the BIS values at all time frames. Following the study period needed to collect the required data, the attending anesthesiologist will have the option to continue general anesthesia with either TIVA or with the traditional inhalational anesthetic. The reversal of the neuromuscular blockade and subsequent tracheal extubation, at the conclusion of surgery, will be performed using the customary criteria employed in anesthetic practice. In addition, the routine protocols used for surgical infection prevention and attenuation of postoperative pain and vomiting will be followed.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
male and female

Inclusion Criteria:

  • 18-65 undergoing orthopedic or gyn surgery
  • ASA status I-III

Exclusion Criteria:

  • pregnant patients
  • uncontrolled hypertension with B/P above 180/100
  • unstable angina
  • end stage liver or kidney disease
  • Pts anticipated to be placed in prone position for surgery
  • Documented allergy to propofol, eggs, soy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01618539

United States, New Jersey
University Hospital
Newark, New Jersey, United States, 07101
Sponsors and Collaborators
Rutgers, The State University of New Jersey
Principal Investigator: Rex Ponnudurai, MD Rutgers/NJMS
  More Information

No publications provided

Responsible Party: Anesthesia, Rex Ponnudurai, MD, Rutgers, The State University of New Jersey Identifier: NCT01618539     History of Changes
Other Study ID Numbers: 2011001109 
Study First Received: June 5, 2012
Last Updated: June 9, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Rutgers, The State University of New Jersey:
Totoal intravenous anesthesia, Bispectral Index Score

Additional relevant MeSH terms:
Fractures, Bone
Wounds and Injuries
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on February 11, 2016